Anti-Kickback Ruling Excludes MSO-Lab Arrangement

April 27, 2026

HHS OIG Advisory Opinion: “No Remuneration” Ends the AKS Analysis

LinkedIn Facebook X ;) Embed

On February 18, 2026, the U.S. Department of Health and Human Services Office of Inspector General (OIG) issued Advisory Opinion 26-02 (AO 26-02), concluding that a proposed arrangement involving a management services organization (MSO) and an affiliated clinical laboratory would not implicate the federal Anti-Kickback Statute (AKS). While many favorable advisory opinions turn on safeguards that mitigate risk, this opinion stands out for a more fundamental conclusion: the arrangement falls outside the AKS altogether because it involves no remuneration.

The Proposed Arrangement

The requestor, an MSO that provides management and administrative services to a group of urgent care centers, proposed to establish an independently owned, offsite clinical laboratory. The lab would bill payors directly, including federal healthcare programs, for performing diagnostic testing for patients of the urgent care centers, among others. Importantly, the urgent care centers and their referring clinicians would have no ownership interest, no revenue share, and no compensation tied to lab referrals.

The MSO would continue providing only administrative services, with no financials flowing between the laboratory and referring providers. The model preserved patient choice for lab services and avoided referral steering.

OIG's Analysis: No Remuneration, No AKS

OIG concluded that the arrangement does not generate "remuneration" under the AKS because referring providers receive no direct or indirect financial benefit-no profit distributions, below-market services, or other transfers of value. That conclusion effectively ended the AKS inquiry.

This framing is notable. OIG did not simply find a "low risk" of AKS violation or rely on safe harbor-like protections; it determined that the threshold statutory element-remuneration-was absent. For healthcare organizations, the opinion underscores a critical but often underleveraged compliance principle: structural separation that eliminates financial linkage to referrals can remove arrangements from AKS scrutiny entirely.

Guardrails Still Matter

Although not necessary to its holding, OIG pointed to features that reinforce the absence of inducement risk, including offsite operations, no embedded personnel, no referral tracking or incentives, and preservation of patient choice. These elements remain important in demonstrating no remuneration. Indeed, OIG cautioned that similar arrangements could raise AKS concerns if structured differently, particularly where there is "any" remuneration flowing to referral sources.

Why This Matters Now

AO 26-02 arrives amid continued government scrutiny of laboratory and MSO-driven models. Over the past year, OIG and DOJ have signaled sustained enforcement interest in arrangements involving clinical laboratories, private equity-backed platforms, and referral-sensitive revenue streams, particularly where compensation structures are complex or indirect. Recent enforcement activity has continued to focus on whether value is flowing to referral sources directly or indirectly, even where formal ownership is absent.

Against that backdrop, AO 26-02 provides a useful counterpoint: where no value flows, affiliation alone is not enough. At the same time, the opinion implicitly reinforces the government's broader message-small deviations from this fact pattern (e.g., shared economics, discounted services, or operational integration that confers value) can change the analysis.

Practical Takeaways

• Eliminating financial linkage: If referral sources receive no value, the AKS may not be implicated at all.
• Form and function both matter: Structural independence should be real, not formalistic-evaluate the economic benefit, however indirect, that may be tied to referrals.
• MSO models remain under scrutiny: This opinion is narrow and fact-specific; similar models with even modest financial overlap may present risk.

• AKS is only one lens: The opinion does not address the federal Physician Self-Referral Law (Stark Law), the False Claims Act, or state laws.
  ;) ;) Report

  Related Posts

• HHS OIG Issues New Guidance on Direct-to-Consumer Prescription Drug Sales and Anti-Kickback Risk

Latest Posts

• HHS OIG Advisory Opinion: “No Remuneration” Ends the AKS Analysis
• Changing Diapers: California Considers Following New York State’s Lead in Enacting a Diaper Labeling Law
• Rogue AI Agents Won’t Be Testifying - You Will: Agentic AI, IP and Liability Risks, and a Path Forward
• IEEPA Tariffs Invalidated: Rising Class Action Risk for Consumer Pricing See more »

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Venable LLP
2026

Written by:

Venable LLP Contact + Follow Valerie Cohen + Follow Ari Markenson + Follow

PUBLISH YOUR CONTENT ON JD SUPRA

• ✔ Increased readership
• ✔ Actionable analytics
• ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Advisory Opinions + Follow Anti-Kickback Statute + Follow Clinical Laboratories + Follow Department of Health and Human Services (HHS) + Follow Government Agencies + Follow Health Care Providers + Follow Healthcare Fraud + Follow Management Companies + Follow OIG + Follow Regulatory Oversight + Follow Government Contracting + Follow Health + Follow more

Venable LLP on:

Solve with 2Captcha

Solve with 2Captcha